RVNC.OQ
Latest Trade
28.64USDChange
-0.20(-0.69%)Volume
144,623Today's Range
-
29.0452 Week Range
-
34.61As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 28.84 |
|---|---|
Open | 28.75 |
Volume | 144,623 |
3M AVG Volume | 10.49 |
Today's High | 29.04 |
Today's Low | 27.92 |
52 Week High | 34.61 |
52 Week Low | 11.80 |
Shares Out (MIL) | 66.55 |
Market Cap (MIL) | 1,905.97 |
Forward P/E | -6.04 |
Dividend (Yield %) | -- |
Revance Therapeutics Sees Q4 Unaudited RHA Collection Rev Of $9.5 Mln To $10 Mln
FDA Defers Approval Of Daxibotulinumtoxina For Injection In Glabellar Lines Due To Covid-19 Related Travel Restrictions
Revance Reports Q3 2020 Financial Results
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. It evaluates DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications: cervical dystonia, adult upper limb spasticity and plantar fasciitis. It has a portfolio of products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription and loyalty digital services.
Industry
Biotechnology & Drugs
Contact Info
1222 Demonbreun Street, Suite 1001
NASHVILLE, TN
37203
United States
+1.510.7423400
http://www.revance.com/Executive Leadership
Angus Charles Russell
Independent Chairman of the Board
Mark J. Foley
President, Chief Executive Officer, Director
Tobin C. Schilke
Chief Financial Officer
Abhay Joshi
Chief Operating Officer, President - R&D and Product Operations
Dwight Moxie
Senior Vice President, General Counsel, Corporate Secretary
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 445.22 |
Price To Book (MRQ) | 5.11 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 47.57 |
LT Debt To Equity (MRQ) | 47.57 |
Return on Investment (TTM) | -56.61 |
Return on Equity (TTM) | -50.94 |
* REVANCE ANNOUNCES LAST PATIENT ENROLLED IN MODIFIED JUNIPER PHASE 2 UPPER LIMB SPASTICITY TRIAL OF DAXIBOTULINUMTOXINA FOR INJECTION
* REVANCE ANNOUNCES POSITIVE RESULTS IN TWO PHASE 2A STUDIES OF DAXIBOTULINUMTOXINA FOR INJECTION FOR THE TREATMENT OF FOREHEAD LINES AND CROW’S FEET, RESPECTIVELY
* REVANCE AND MYLAN TO ADVANCE DEVELOPMENT PROGRAM FOR BIOSIMILAR TO BOTOX®
* REVANCE ANNOUNCES AGREEMENT TO ACQUIRE HINTMD AND ITS PROPRIETARY FINTECH PLATFORM FOR AESTHETIC PRACTICES
* REVANCE REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS, PROVIDES CORPORATE UPDATE
* REVANCE AND MYLAN BIOSIMILAR TO BOTOX® PROGRAM DECISION TO EXTEND BEYOND APRIL 30, 2020
* REVANCE THERAPEUTICS INC - PDUFA TARGET ACTION DATE FOR DAXI IN GLABELLAR LINES OF NOV 25, 2020
* REVANCE REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS, PROVIDES CORPORATE UPDATE
* REVANCE ANNOUNCES PRICING OF $250 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027
* REVANCE ANNOUNCES PROPOSED PRIVATE OFFERING OF $200 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027 Source text for Eikon: Further company coverage:
* REVANCE THERAPEUTICS INC - ANNOUNCES PROPOSED PRIVATE OFFERING OF $200 MILLION OF CONVERTIBLE SENIOR NOTES DUE 2027
A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year.
Medical aesthetics company Revance Therapeutics Inc said on Tuesday that its long-acting injectable drug was successful in reducing moderate-to-severe frown lines in a late-stage study.
* REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018 Source text for Eikon: Further company coverage:
Mylan NV on Wednesday struck a licensing agreement with Revance Therapeutics Inc to develop a biosimilar of Allergan Plc's blockbuster Botox wrinkle treatment.
* REVANCE THERAPEUTICS INC - REITERATES ITS FINANCIAL GUIDANCE PROVIDED IN JANUARY 2018
* REVANCE THERAPEUTICS SAYS CO, MYLAN IRELAND LIMITED ENTERED INTO COLLABORATION DEAL- SEC FILING
* REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS
* REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.